Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

PATIENT POPULATION: All patients with CML in any phase of the disease (chronic, accelerated or blast phase) that has received treatment with any tyrosine kinase inhibitor (eg, imatinib, dasatinib, nilotinib) regardless of prior treatment history that has had at least one clinic visit at MDACC will be eligible. STUDY PLAN: The following information will be collected: * Demographic information including age, gender, ethnicity, education, and work history. * All laboratory values obtained at MDACC or other institutions, including CBC, blood chemistries, electrolytes, bone marrow aspirations and biopsies, cytogenetic analyses, mutation analysis, FISH, and PCR, and other tests obtained during regular care of these patients. * Treatment history including starting and stopping dates, doses, treatment interruptions, dose changes and reasons for dose modifications. * Information about toxicity including type, grade, dates of onset and resolution, interventions to manage toxicity, and sequelae. * Information regarding pregnancy or conception during imatinib therapy for both male and female patients, including dates of pregnancy, outcome of pregnancy, interventions during pregnancy, management of CML during pregnancy, complications during pregnancy, status of the product, condition of the born child, and information on lactation. * This information will be reviewed from the documents received as part of the routine communication with the local oncologist or from the studies obtained at MDACC. * There will be no treatment changes or recommendations as a result of this study. This study will be strictly limited to review of charts. Patients will continue their treatment as recommended by their local oncologist and treating physician at MDACC. * These results will be compared to similar patients treated with imatinib in the context of clinical trials both from published literature and from other studies conducted at MDACC. The efficacy, safety and prognostic markers will be compared. * We will review data from July 1, 1998 to August 1, 2019. SAMPLE SIZE: Approximately 3000 charts will be reviewed.